The same MMP2 promoter polymorphisms have been associated with increased susceptibility to Alzheimer’s disease, vascular dementia, and Parkinson’s disease, likely due to enhanced transcriptional activity and blood–brain barrier permeability [12,37]. This evidence concerns the gene MMP2 and early-onset autosomal dominant Alzheimer disease.